(R)-NODAGA-PSMA: A versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Gourni, Eleni ^a,b,d   Canovas, Coline ^c   Goncalves, Victor ^c   Denat, Franck ^c   Meyer, Philipp T ^b   Maecke, Helmut R ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; COPPER 64; GALLIUM 68; GLUTAMIC ACID; INDIUM 111; LYSINE; NODAGA PHENYLALANYLPHENYLALANYL DEXTRO LYSINE (SUBEROYL) LYSINE UREA GLUTAMIC ACID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UREA; 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; SINGLE HETEROCYCLIC RINGS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LIPOPHILICITY; LNCAP CELL LINE; METASTASIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG SCREENING; IMAGE PROCESSING; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ACETATES; ANIMALS; ANTIGENS, SURFACE; FEMALE; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; MICE, INBRED BALB C; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957546202     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145755     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29. doi: 10.3322/caac.21254 PMID: 25559415
2. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004; 6(suppl 10): 13.
3. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-spacific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology. 2001; 57: 1179-1183. PMID: 11377343
4. Wright GLJ, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996; 48: 326-334. PMID: 8753752
5. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathol. 2007; 38: 696-701.
6. Liu T, Toriyabe Y, Kazak M, Berkman CE. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry. 2008; 47: 12658-12660. doi: 10.1021/bi801883v PMID: 18983168
7. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7: 927-936. PMID: 2449118
8. Troyer JK, Becket ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997; 30: 232-242. PMID: 9111600
9. Vallabhajosula S, Kuji I, Mamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005; 46: 634-641. PMID: 15809486
10. 89Zr-DFO-J591 for immuno-PET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51: 1293-1300. doi: 10.2967/jnumed.110.076174 PMID: 20660376
11. 89Zr-7E11 immuno-PET. J Nucl Med. 2011; 52: 1608-1615. doi: 10.2967/jnumed.111.092098 PMID: 21908391
12. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006; 66: 1359-1370. PMID: 16894535
13. 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate. 2010; 70: 1413-1421. doi: 10.1002/pros.21176 PMID: 20687214
14. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007; 25: 540-547. PMID: 17290063
15. 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Can Res. 2005; 11: 7195-7200s.
16. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents. J Med Chem. 2004; 47: 1729-1738. PMID: 15027864
17. Maresca KP, Hillier SM, Femia FL, Keith D, Barone C, Joyal JL, et al. A series of halogenated heterodimeric inhibitors of prostate-specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009; 52: 347-357. doi: 10.1021/jm800994j PMID: 19111054
18. Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008; 51: 7933-7943. doi: 10.1021/jm801055h PMID: 19053825
19. Shawn MH, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel-glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69: 6932-6940. doi: 10.1158/0008-5472.CAN-09-1682 PMID: 19706750
20. Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008; 51: 4504-4517. doi: 10.1021/jm800111u PMID: 18637669
21. 99mTc-radioimaging agents. Mol Pharm. 2009; 6: 790-800. doi: 10.1021/mp9000712 PMID: 19361232
22. Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2015; 55: 1791-1798.
23. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and prelinical evaluation of DOTAGA-conjugated PSMA ligands for functiona limaging and endoradiotherapy of prostate cancer. EJNMMI Research. 2014; 4: 63. doi: 10.1186/s13550-014-0063-1 PMID: 26116124
24. 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med. 2015; 56: 628-634. doi: 10.2967/jnumed.114.149062 PMID: 25722448
25. 68Ga-Complex lipophilicity and the targeting property of a urea based PSMA inhibitor for PET imaging. Bioconjugate Chem. 2012; 23: 688-697.
26. Benešová M, Schäfer, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evauation os a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate-cancer. J Nucl Med. 2015; 56: 914-920. doi: 10.2967/jnumed.114.147413 PMID: 25883127
27. 177Lu-labeled PSMA I&T: optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med. 2015; 56: 1169-1176. doi: 10.2967/jnumed.115.158550 PMID: 26089548
28. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010; 53: 5333-5341. doi: 10.1021/jm100623e PMID: 20568777
29. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014; 57: 2657-2669. doi: 10.1021/jm401921j PMID: 24533799
30. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging ofrecurrent prostate cancer. Lancet Oncol. 2011; 12: 181-191. doi: 10.1016/S1470-2045(10)70103-0 PMID: 20599424
31. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3: 81-85. PMID: 9815541
32. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42: 197-209. doi: 10.1007/s00259-014-2949-6 PMID: 25411132
33. 68Ga radiopharmaceutical chemistry. Curr Top Med Chem. 2010; 10: 1633-1668. PMID: 20583984
34. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiphar Radiopharm. 2009; 24: 379-393.
35. Craig AC, Helps IM, Parker D, Adams H, Bailey NA, Williams MG, et al. Crystal and molecular structure of a seven-coordinate chloroindium(III) comple of 1,4,7-triazacyclononanetriacetic acid. Polyhedron. 1989; 20: 2481-2484.